Compare Synopsys, Inc. (SNPS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs BIO-TECHNE Corp — how do they compare? Synopsys, Inc. trades at $388.33 (market cap $72.47B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Synopsys, Inc. is far larger — about 6.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | TECH | |
|---|---|---|
Market Cap | $72.47B | $11.16B |
Sector | Technology | Health |
52-Week High | $645.59 | $72.12 |
52-Week Low | $378.46 | $43.31 |
Enterprise Value | $80.82B | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
